Health & Environmental Research Online (HERO)


Print Feedback Export to File
6985043 
Journal Article 
Immunomodulation by Quillaja saponaria adjuvant formulations: In vivo stimulation of interleukin 12 and its effects on the antibody response 
Villacreseriksson, M; Behboudi, S; Morgan, AJ; Trinchieri, G; Morein, B 
1997 
Yes 
Cytokine
ISSN: 1043-4666
EISSN: 1096-0023 
9 
2 
73-82 
English 
9071557 
WOS:A1997WM57500001 
The capacity of adjuvants to activate Ag-presenting cells during the induction of the primary immune response is of critical importance for the development of protective immunity to a number of pathogens. In this context, interleukin 12 (IL-12) has a key role by controlling the differentiation of T helper cells and favouring the expansion of Th1 cells. The capacity of iscoms with influenza virus Ag (flu-iscoms) and iscom matrix with EBV gp340 Ag to induce IL-12 was analysed in mice. The flu-iscom drives the immune response towards a Th1 type subsequent to IL-12 induction as measured in the serum of H2b, H2d and H2k mice. The iscom presenting the Ag and adjuvant in the same particle was considerably more efficient than the formulation of matrix and Ag in separate particles. Inhibition experiments with mAb neutralizing IL-12, interferon gamma (IFN-gamma) or IL-4, the latter two cytokines representing the Th1 and Th2 type of responses, showed that iscoms induce a broader immune response than that involving IL-12. This was shown by the additional effect that IL-4 neutralization had on the immune response to iscoms. Anti-IL 12 reduced the specific total Ab as well as IgG1, IgG2a and IgG2b while anti-IL 4 influenced the response to iscom by decreasing IgG2a and increasing IgG1. Further, the neutralization experiments indicate that IL-12 has a broader effect than IFN-gamma on the Ab response by influencing the production of IgG1, IgG2a and IgG2b. 
adjuvant; immunomodulation; interleukin-12; iscoms